Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pushing Hard On PD-1, Merck Signs Trio Of Combo Development Deals

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck’s oncology build-up is continuing, even as it tightens focus and squeezes spending in other parts of its business as part of an ongoing “reshaping” that CFO Peter Kellogg said will help to maximize “core in-line assets and key pipeline programs” that are critical for growth.

Advertisement

Related Content

Dr. Reddy’s Chairman GV Prasad On Innovation, Biosimilars And Global Challenges: An Interview With PharmAsia News
Emerging Markets Earnings Roundup: Merck, AstraZeneca (Part 6)
Two Approaches To PD-1 Blocker Pediatric Studies Could Help Clarify Biomarker’s Role
Merck Bets Big On Oncology In New R&D Strategy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076916

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel